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In this issue ofStructure, Chen et al. present structures of the FERM-containing protein tyrosine phosphatase
PTPN3 in complex with a phosphopeptide fragment of susbtrate epidermal growth factor receptor pathway
substrate, providing detailed information on substrate specificity.Protein tyrosine phosphatases (PTPs)
play critical roles in cell signaling path-
ways. Together with the kinases, they
control the balance of phosphorylated
species, enabling specific and varied
signaling responses. A large number of
enzymes and substrates are involved
in these pathways, and knowledge of
the specific cellular substrates of the
specific PTPs is important for a more
complete understanding of the complex
interactions that provide the signaling
cascades. Dysfunction of PTPs has been
associated with a number of human dis-
eases including cancers, autoimmune
disorders, diabetes, and neurological
diseases.
The work presented by Chen et al.
(2015) describes studies that help provide
a more coherent understanding of the
molecular basis of substrate specificity
in the FERM-containing subfamily ofnonreceptor PTPs (Chen et al., 2015).
This subfamily contains PTPs N3, N4,
N13, N14, and N21. These enzymes are
characterized by the presence of an
N-terminal FERM (4.1 protein [F], ezrin,
radixin, and moesin) plasma membrane-
localization domain and a C-terminal
catalytic domain. Specifically, the work
here examines the molecular interactions
that govern the interaction of the PTP
N3 (PTPN3) with substrate epidermal
growth factor receptor (EGFR) pathway
substrate (Eps15). Eps15 is a scaffolding
adaptor that regulates endocytosis and
trafficking of the EGFR that has recently
been identified as a substrate for PTPN3
(Li et al., 2014).
By taking a small phosphopeptide
fragment of the substrate Eps15 and
examining its interaction with a series
of variants of the catalytic domain of
PTPN3, the authors have revealed keyinteractions that likely determine both
substrate recognition and the catalytic
activity of the complex. Several structures
are presented, which, combined with the
kinetic assessment of the dephosphory-
lation reaction of the phosphopeptide
substrate, provide interesting new insight
into the molecular recognition processes
involved.
The structure of a catalytically inactive
variant of the PTPN3 in combination with
the phosphopeptide fragment of Eps15
(Figure 1) reveals an important interaction
between H812 of the enzyme and a
proline residue adjacent to the phospho-
tyrosine of the peptide substrate, which
results in an atypical conformation of
the C-terminal part of the peptide sub-
strate. The importance of proline in deliv-
ering this conformation was evaluated
by assessment of a variant synthetic
phosphopeptide fragment in which the
Figure 1. Structure of PTPN3
Structure (PDB code 4RH5) of the catalytic domain
of PTPN3 (D811A/C842S mutant, orange) in
complex with phosphopeptide fragment of Eps15
(residues 846–854, cyan).
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substrate-enzyme pairing, the atypical
conformation was lost. Likewise the role
of H812 was further investigated by the
preparation of variant protein with the
H812F substitution. This substitution
enacts a natural occurrence of a phenylal-
anine in this position in the PTP 1B
(PTP1B). Both this variant of PTPN3
and the PTP1B demonstrated higher
Michaelis constants for the reaction with
the synthetic phosphopeptide.
A further set of kinetic studies and
structures allow an examination of the
molecular basis of the selectivity of the
PTPN3 for the Eps15 substrate in contrast
to the other subfamily phosphatases, all
of which contain an equivalent to H812.
Sequence comparisons led to mutagen-
esis studies that determined the impor-
tance of tyrosine (Y676) in the pTyr loop
and methionine (M883 in PTPN3) in the
WPD loop for substrate recognition. In
addition, the importance of an aspartate
in the WPD loop rather than a glutamate
(as is found in PTP21) for catalytic activity
was demonstrated and the molecularbasis for the low activity of this PTP and
the PTPN3 D811E variant was revealed
by a structure of this mutant in complex
with the Eps15-phosphopeptide.
These studies are elegantly comple-
mented by in vivo experiments to test
whether residues H812 and D811 of
PTPN3 were required to regulate Eps15-
dependent EGFR signaling in cultured
cells. Whereas wild-type PTPN3 sig-
nificantly decreased EGF-induced phos-
phorylation of Eps15 in human embryonic
kidney HEK293T cells following trans-
fection, ectopic expression of D811E or
H812F mutant form of PTPN3 did not
reduce phosphorylation of Eps15.
There is significant interest in gaining
information on the structure of the PTPs
to support an understanding of their bio-
logical roles (Hardy et al., 2015; Lountos
et al., 2015; Ozek et al., 2014; Zhang
et al., 2015). Recently, PTPN14 was
reported to suppress metastasis by
reducing intracellular protein trafficking
through the secretory pathway, and RIN1
(Ras and Rab interactor 1) and PRKCD
(protein kinase C-delta) were identified
as binding partners and substrates of
this phosphatase (Belle et al., 2015).
Argonaute 2 was recently identified as
a direct substrate of PTP1B, resulting in
the regulation of gene silencing in onco-
genic RAS-induced senescence (Yang
et al., 2014). Additionally, structures of
PTPN18 in complex with HER2 phos-
phopeptides have shown the molecular
details of the interaction between
PTPN18 and specific HER2 phosphoryla-
tion sites (Wang et al., 2014).
PTPN3 has attracted considerable
recent attention for its role in cancer,
particularly the role it plays in partnership
with the mitogen-activated kinase p38
gamma. Very recently, the same group
determined the structure of this protein
in combination with its kinase partner.
These structures reveal extensive interac-Structure 23, April 7, 2015tions of p38 gamma across multiple do-
mains of the phosphatase (Chen et al.,
2014).
PTPs play critical roles in complex
signal transduction cascades, and under-
standing the molecular details that govern
their substrate specificities may assist a
complete description of these intricate
pathways and provide opportunities for
the development of therapeutics for the
diseases with which these enzymes are
associated.REFERENCES
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